Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Violence 'never part' of break-in plan, court told - 2Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- 3Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- 4UN warns civil liberties under threat due to war in Middle East
- 5Improving as a Cook: Culinary Experiences in the Kitchen
- Relive NASA's historic Artemis 2 launch to the moon in these stunning photos
- New science points to 4 distinct types of autism
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- 'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law
- The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- Executed Iranian nuclear scientist confessed to aiding Israel after torture, threats against mother
- the Wild in Style: The Reduced Portage Mustang's Bold Heritage
- Examination In progress into Abuse of Japanese Government-Supported Advance
- This Luxurious Thermal Spa In Italy Is Perfect For A Relaxing Escape While Visiting Milan
